1-4 of 4
Pierre Reusser
Close
Sort by
Journal Articles

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

Clinical Trials & Observations
Hermann Einsele, Pierre Reusser, Martin Bornhäuser, Peter Kalhs, Gerhard Ehninger, Holger Hebart, Yves Chalandon, Nicolaus Kröger, Bernd Hertenstein, Frank Rohde, for the EBMT Working Group on Infectious Disease
Journal: Blood
Blood (2006) 107 (7): 3002–3008.
https://doi.org/10.1182/blood-2005-09-3786
Published: 2006
Journal Articles

Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD.

Hermann Einsele, MD, Pierre Reusser, MD, Holger Hebart, MD, Bernd Hertenstein, MD, Martin Bornhaeuser, MD, Gerhard Ehninger, MD, Nikolaus Kroeger, MD, Peter Kahls, MD, Yves Chalandon, MD, Frank Rohde
Journal: Blood
Blood (2004) 104 (11): 2239.
https://doi.org/10.1182/blood.V104.11.2239.2239
Published: 2004
Journal Articles

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation: Presented in part at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999 (abstract H144).

Clinical Trials & Observations
Pierre Reusser, Hermann Einsele, John Lee, Liisa Volin, Montserrat Rovira, Dan Engelhard, Jürgen Finke, Catherine Cordonnier, Hartmut Link, Per Ljungman
Journal: Blood
Blood (2002) 99 (4): 1159–1164.
https://doi.org/10.1182/blood.V99.4.1159
Published: 2002
Journal Articles

Cytomegalovirus-Specific T-Cell Immunity in Recipients of Autologous Peripheral Blood Stem Cell or Bone Marrow Transplants

Pierre Reusser, Rudolf Attenhofer, Holger Hebart, Claudine Helg, Bernard Chapuis, Herrmann Einsele
Journal: Blood
Blood (1997) 89 (10): 3873–3879.
https://doi.org/10.1182/blood.V89.10.3873
Published: 1997